Mark J. Zoller

Nessuna posizione attualmente

70 anni

Consumer Services

Consumer Non-Durables

Health Technology

Profilo

Mark J.
Zoller joined Senomyx, Inc. in March 2000 as Vice President of Research.
He became Senior Vice President of Research and Chief Scientific Officer for Senomyx in June 2001.
From May 1992 to December 1999, Dr. Zoller held various scientific management positions at ARIAD Pharmaceuticals, including Senior Vice President of Genomics and Scientific Director of the Hoechst-ARIAD Genomics Center.
He received a BA degree in Chemistry from Pomona College and a PhD degree in Chemistry from the University of California, San Diego.

Precedenti posizioni note di Mark J. Zoller

Società	Posizione	Fine
SENOMYX INC.	Direttore Tecnico/Scientifico/R&S	17/06/2009
ARIAD PHARMACEUTICALS, INC.	Corporate Officer/Principal	01/12/1999

Vedi nel dettaglio l'esperienza di Mark J. Zoller

Formazione di Mark J. Zoller

Pomona College	Undergraduate Degree
University of California San Diego	Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Mark J. Zoller

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Senomyx, Inc. Senomyx, Inc. Food: Specialty/CandyConsumer Non-Durables Senomyx, Inc. engages in the development and commercialization of flavor ingredients for the packaged food, beverage, and ingredient supply industries. It develops high intensity sweeteners, savory flavors, bitter taste blockers, and cooling agents. The company was founded by Paul A. Grayson, Lubert Stryer, Yon Chien Tsien, Denis Baylor, Harold McGee, and Charles Zuker on September 16, 1998 and is headquartered in San Diego, CA.	Consumer Non-Durables
ARIAD Pharmaceuticals, Inc. ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA.	Health Technology